INS and Insulin resistance: In the present study, we examined the maintenance of plasma glucose-lowering effects with a 24-week MK-0941 treatment in Goto-Kakizaki rats, a diabetes model whose average plasma glucose levels were similar to the patients in the clinical study, around 240 mg/dL (Fig 2B), and exhibited both insulin resistance and decreased insulin secretion [16, 17].